Opus Genetics, Inc. (IRD) — Cash Flow-to-Debt Ratio
Opus Genetics, Inc. (IRD) has a Cash Flow-to-Debt Ratio of -0.28x as of December 2025, meaning its operating cash flow of $-9.83 Million could theoretically repay 0% of its total liabilities ($34.90 Million) in one year. See IRD cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Opus Genetics, Inc. Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Opus Genetics, Inc. across 7 annual periods. Also explore net asset momentum of Opus Genetics, Inc. to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Opus Genetics, Inc. (2019–2025)
Year-by-year debt coverage analysis for Opus Genetics, Inc.. For market capitalisation and broader financial context, see market cap of Opus Genetics, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.01x | $-35.25 Million | $34.90 Million | ▼ -19.0% |
| 2024 | -0.85x | $-25.58 Million | $30.14 Million | ▼ -208.5% |
| 2023 | -0.28x | $-1.11 Million | $4.04 Million | ▼ -105.3% |
| 2022 | 5.20x | $14.31 Million | $2.75 Million | ▲ +203.5% |
| 2021 | -5.02x | $-19.37 Million | $3.85 Million | ▼ -2202.7% |
| 2020 | -0.22x | $-6.80 Million | $31.15 Million | ▲ +43.3% |
| 2019 | -0.38x | $-3.59 Million | $9.34 Million | — |